INTRODUCTION
============

American Tegumentary Leishmaniasis (ATL) is an infectious disease that affects the skin and mucous membranes, showing distinct clinical manifestations determined by an equilibrium between parasitic factors (tropisms, virulence, resistance and species) and the host immune response^[@B1]\ -\ [@B3]^ . The main clinical forms are cutaneous leishmaniasis (CL), muco-cutaneous leishmaniasis (MCL) and disseminated cutaneous leishmaniasis (DCL). The cutaneous leishmaniasis (CL) is caused by *L. (V.) braziliensis* , *L. (V.) guyanensis* , *L. (L.) amazonensis* and *L. (V.) naiffi* . The muco-cutaneous leishmaniasis (MCL) is caused by *L. (V.) braziliensis* and the disseminated cutaneous leishmaniasis (DCL) is caused by *L. (L.) amazonensis* and *L. (L.) mexicana* ^[@B4]^ .

According to the World Health Organization (WHO), leishmaniasis is one of the most important neglected tropical diseases due to its high detection coefficient and capacity to produce deformities. This disease affects mainly individuals of low socioeconomic level, and the number of cases in endemic areas have increased significantly in recent years^[@B5]\ -\ [@B8]^ . It is estimated that 350 million people are at risk of contracting the infection, and the annual incidence is estimated at about two million new cases^[@B9]^ .

In Brazil, about 20 thousand cases/year are recorded, with an incidence coefficient of 10.3 cases/100,000 inhabitants in the last five years. In 2015, the Brazilian North region had the highest incidence rate (51.1 cases/100,000 inhabitants), followed by the Midwest (19.0 cases/100,000 inhabitants) and the Northeast (9.1 cases/100,000 inhabitants)^[@B10]^ .

The diagnosis of leishmaniasis is based on epidemiological data, clinical characteristics and laboratory test results, including parasitological examination, serological and molecular methods as well as the Montenegro skin test^[@B4]^ .

Clinical practice guidelines recommend multiple testing of active cutaneous lesion samples. Thus, the parasitological diagnosis is based on the evidence of the parasite through direct microscopy of smears and/or culture, requiring a trained laboratory staff^[@B11]\ ,\ [@B12]^ . In addition, these tests require invasive procedures of sample collection, which limit their use^[@B13]^ . Even though the direct detection of parasites has low sensitivity, it is still the gold standard for the laboratory diagnosis of ATL. The Montenegro skin test (MST), with a sensitivity rate of 86.4-100%^[@B14]^ , is the main diagnostic test in primary care. In the presence of a suspicious cutaneous lesion, MST supports the diagnosis of *Leishmania* infections. However, MST results may be influenced by the clinical presentation and the disease duration^[@B14]^ .

The association of MST with molecular biology methods, especially in reference treatment centers, offers higher diagnostic accuracy as well as good sensitivity and specificity. Therefore, a combination of diagnostic methods is usually required to obtain accurate results^[@B15]\ ,\ [@B16]^ . There is a need to develop faster, more effective and simpler assays for the diagnosis of this disease^[@B17]^ . Among these tests, serology has been the most widely used method in epidemiological studies, providing additional support for disease control measures. However, since most patients have low antibody titers against *Leishmania* species, this method may be associated with a relatively high proportion of false negative results. In addition, different species of *Leishmania* overlap the distribution of *Trypanosoma cruzi* in many geographic regions, increasing the risk of cross-reactions in these endemic areas^[@B18]\ ,\ [@B19]^ .

ELISAs are useful diagnostic tools for ATL, being fast and relatively affordable. However, their accuracy is variable^[@B20]\ ,\ [@B21]^ . Several studies have selected proteins common to *Leishmania* species to develop an assay capable of detecting the disease irrespective of the etiological agent species. Among the proteins used, cytochrome c oxidase VII (CcOx), IgE-dependent histamine-releasing factor (HRF) and histones have been used^[@B21]\ ,\ [@B22]^ .

Recently, several recombinant proteins have been successfully developed and used for the serological diagnosis of ATL, showing better sensitivity and specificity. In ELISAs, the recombinant antigens rK108, rLbHyM, rLHHs, rHSPH83, RA2, rLb6H, and rLb8E were used^[@B23]\ -\ [@B27]^ .

Promising results in several studies on ELISAs using recombinant antigens have been reported. The successful implementation of these methods reflects their good performance. Therefore, this study provides a brief systematic review of studies on the accuracy of available serological tests, aiming to evaluate the accuracy of these tests for the detection of antibodies against *Leishmania* species.

MATERIALS AND METHODS
=====================

The protocol of this systematic review was published in the International Prospective Record of Systematic Reviews (PROSPERO 2018: CRD42018114275) before its implementation and is described in the Complementary Materials. The protocol and the final report were developed based on the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy^[@B28]^ .

Review question
---------------

What is the diagnostic accuracy of ELISAs with novel antigens compared to the standard serological test based on soluble antigens of *Leishmania* species (SLA) for the serological diagnosis of American Tegumentary Leishmaniasis (ATL)?

Inclusion and exclusion criteria
--------------------------------

This review considered studies that included patients with ATL that were diagnosed by at least one of the parasitological gold standards (Montenegro skin test, direct microscopy of smears and/or culture) or by the Polymerase Chain Reaction (PCR). In addition, we included studies that evaluated the diagnostic accuracy of ELISAs based on novel antigens for the serological diagnosis of ATL, as well as those using soluble *Leishmania* antigens (SLA) in order to detect antibodies against species of *Leishmania* that cause ATL. Studies that analyzed the accuracy of ELISAs but did not define the endemic controls were excluded.

Types of study
--------------

Cross-sectional studies based on diagnosis by serological tests providing detailed measurements of sensitivity, specificity, positive and negative predictive values, likelihood ratio and area under the curve (AUC), were included.

Search strategy
---------------

An initial search limited to MEDLINE was performed by using the MeSH index terms and related keywords. This search was performed followed by the analysis of words along the text that were also mentioned in the titles and summaries and terms of the index used to describe the studies. A second search using all the identified keywords and index terms was performed on all included databases. In a third search, the reference list of all dissertation theses with clearly detailed accuracy values were evaluated. Considering that ATL is a disease that affects the American continent, the search was limited to English, Spanish and Portuguese. The search for primary literature was not limited to the initial date and was completed in October 2018.

The search for studies used the following databases: PubMed, Regional Portal of the Virtual Health Library (BVS), Brazilian Society of Dermatology, Virtual Health Library (IBECS), Literature in the Health Sciences in Latin America and the Caribbean (LILACS), Medical Literature Analysis and Retrieval System Online (Medline), Elsevier Embase, Cochrane Library, The National Institute for Health and Care Excellence (NICE), and Cumulative Index to Nursing and Allied Health Literature (CINAHL). The MeSH Index Terms searched were: Leishmaniasis, cutaneous Leishmaniasis, Mucocutaneous; ELISA; Serological, Test; Diagnosis; *Leishmania* ; Serology; Data Accuracy. The keywords used were: "American Tegumentary Leishmaniasis, Serodiagnosis *,* Specificity and Sensitivity. The terms were combined via the boolean operators "AND" and/or "OR" to compose the search strings.

Methodological quality assessment
---------------------------------

The articles selected for data collection were read by two independent reviewers to evaluate the methodological validity of each text before their inclusion in this review. The standardized critical evaluation instrument QUADAS 2 was used, which was released in 2011 after the revision of the original QUADAS (Quality Assessment of Diagnostic Accuracy Studies)^[@B29]\ ,\ [@B30]^ . All disagreements between reviewers were resolved through discussion or by a third reviewer.

Data extraction
---------------

Quantitative data were extracted from the texts included in this review using the STARD (Standards for Reporting Studies of Diagnostic Accuracy) checklist^[@B31]^ . All disagreements between both reviewers were resolved through discussion or by a third reviewer.

Data synthesis
--------------

The results are shown in three groups: 1) Novel-based ELISA (novel antigens); 2) SLA-based ELISA (soluble antigens of *Leishmania* ) and 3) immunofluorescence assays (IFA). The development of a meta-analysis to analyze the general performance of the tests was not performed as there was only one study for each ELISA based on a given novel antigen and also due to a great heterogeneity in the standard ELISA based on SLA. Data found in this study will be shown only in a narrative and qualitative way.

RESULTS
=======

Our research resulted in 315 manuscripts related to the serology of leishmaniasis by the combined application of descriptors in the databases described above. Only 14 studies remained ( [Table 1](#t1){ref-type="table"} )^[@B20]\ ,\ [@B22]\ ,\ [@B24]\ ,\ [@B25]\ ,\ [@B27]\ ,\ [@B32]\ -\ [@B40]^ after applying the eligibility criteria (duplicate texts, articles related to other topics, texts excluded due to review or quality method criteria). The studies evaluated the diagnostic accuracy of different specific and novel antigens. The function of some of these antigens are not known, for instance conserved hypothetical proteins such as rLiHyS, rLbHyM, LiHypA and LbrM.30.3350. Other antigens are heat shock proteins (HSP),rLb8E, rLb6H and HSP83.1, histamine-releasing factor (HRF), cytochrome C oxidase VII (CcOx), tryparedoxin peroxidase, eukaryotic initiation factor 5a, enolase, and γ-Tubulin. These assays were compared to standard ELISAs using soluble antigens from different *Leishmania* species (SLA), enriched membrane fraction and indirect immunofluorescence (IFA) assays. The results of our search strategy are shown in a PRISMA flowchart ( [Figure 1](#f01){ref-type="fig"} ).

Table 1A summary of the included studies.JournalYearAuthorSamplesECCDCLMLParasitol Int.2018Dias DS02335235Parasitol Res.2017Lima MP20252510Clin Microbiol.2017Sato CM2196891Cell Immunol.2017Carvalho AMRS27304015Vet Parasitol.2016Coelho EA1212208Clin Vaccine Immunol.2015Duarte MC23203010Braz J Infect Dis.2015Soares KA988024Clin Vaccine Immunol.2014Menezes-Souza D45205020J Clin Lab Anal.2010Cataldo JI76760Braz J Infect Dis.2009Szargiki R871310J Clin Lab Anal.2009Nascimento LD1891890Trans R Soc Trop Med Hyg.2009Barroso-Freitas APT7420920Acta Trop.2008Vidigal C de P484830Bol Malariol Salud Ambient.2007Añez N871040[^2]

Figure 1A flowchart of the steps performed in the systematic review.

The methodological quality assessment revealed that the studies included in this systematic review had a "low risk of bias" in the domains of patient selection, index test, reference standard as well as flow and timing. Regarding the "applicability concerns," the selected studies showed a low concern in the domains of patient selection, index test and reference standard ( [Figure 2](#f02){ref-type="fig"} ). Data extracted from the final selection are shown in [Table 2](#t2){ref-type="table"} .

Figure 2Assessment of methodological quality domains in all the studies. Proportions of studies rated as "high," "unclear," and "low" are presented.

Table 2PRISMA checklist.Section/topic\#Checklist itemReported on page \#**TITLE**Title1Identify the report as a systematic review, meta-analysis, or both.Title**ABSTRACT**Structured summary2Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.Abstract**INTRODUCTION**Rationale3Describe the rationale for the review in the context of what is already known.IntroductionObjectives4Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study design (PICOS).Introduction and Methods: Review Question.**METHODS**Protocol and registration5Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.MethodsEligibility criteria6Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.Methods: Inclusion CriteriaInformation sources7Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.Methods: Search StrategySearch8Present full electronic search strategy for at least one database, including any limits used, so that that it could be repeated.Methods: Search StrategyStudy selection9State the process for selecting studies (i.e., screening, eligibility, included in systematic review and, if applicable, included in the meta-analysis).Methods: Study StrategyData collection process10Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming the data obtained by investigators.Methods: Data extractionData items11List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.Methods: Data extraction/Quality assessmentRisk of bias in individual studies12Describe methods used for assessing risk of bias of individual studies (including specification of whether this was performed in the study or outcome level), and how this information is to be used in any data synthesis.NASummary measures13State the principal summary measures (e.g., risk ratio, difference in means).NASynthesis of results14Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2^) for each meta-analysis.NARisk of bias across studies15Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).NAAdditional analyses16Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.Methods: Data Synthesis**RESULTS**Study selection17Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.Results (Figure 1)Study characteristics18For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.Results (Table 1)Risk of bias within studies19Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).NAResults of individual studies20For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.Results: Figure 2 and 3Synthesis of results21Present results of each meta-analysis done, including confidence intervals and measures of consistency.NARisk of bias across studies22Present results of any assessment of risk of bias across studies (see Item 15).NAAdditional analysis23Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\]).Results**DISCUSSION**Summary of evidence24Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).DiscussionLimitations25Discuss limitations at study and outcome levels (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).DiscussionConclusions26Provide a general interpretation of the results in the context of other evidence and implications for future research.Conclusion**FUNDING**Funding27Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.NA [^3]

In the 14 studies included in this systematic review, 2,478 ELISAs were distributed among 1,155 (46.6%) samples from patients with ATL, 870 (35.1%) were endemic controls and 453 (18.3%) analyses were evaluated cross-reactions with serum samples from patients with Chagas disease. Only seven studies distributed the samples of patients with ATL according to the clinical form of the disease into the categories cutaneous leishmaniasis (CL) and muco-cutaneous leishmaniasis (MCL) ( [Table 1](#t1){ref-type="table"} ). Regarding the comparisons with IFA, 417 tests were performed in only two studies. It is important to mention that cross-reactions with other dermatological diseases were also analyzed in a few of the included studies (histoplasmosis, malaria, paracoccidioidomycosis, toxoplasmosis, tuberculosis, and leprosy). Regarding the geographic distribution, 89.6% of the samples were collected in Brazil and only 10.4% in Venezuela.

Synthesized measurements of accuracy
------------------------------------

A global estimate of the accuracy of ELISAs used as serological methods in the diagnosis of ATL was summarized.

Based on recombinant antigens and other known proteins, novel antigens (HSP, rLb8E, rLb6H, HRF, LiHypA, CcOx, trypidoxin peroxidase, eukaryotic initiation factor 5, enolase and γ-tubulin) and standard SLA-based ELISAs were compared ( [Table 3](#t3){ref-type="table"} ).

Table 3Accuracy of ELISAs and IFA for diagnosis of ATL using different *Leishmania* antigens. Summary overall of accuracy for each *Leishmania* antigen used in the ELISAs.Author, yearAntigenCountryAccuracy StudySensitivityCI 95%SpecificityCI 95%PPVCI 95%NPVCI 95%LR+AccuracyAUCCI 95%Dias DS, 2018Novels AntigensrLiHySBrazil100%94.7 - 100100%93.8 - 100100%94.7 - 100100%93.8 - 100N.CN.CN.CN.CLima MP, 2017Novels AntigensrLbHyMBrazil100%89.4 - 99.998.0%89.4 - 99.9N.C.N.C.N.C.N.C.50N.C.N.CN.CSato CM, 2017Novels AntigensrLB8EBrazil100%94.7 - 10098.5%92.1 - 100N.C.N.C.N.C.N.C.N.C.99.2%N.CN.CrLb6HBrazil100%94.7. 10098.5%92.1 - 100N.C.N.C.N.C.N.C.N.C.9.2%N.CN.CCarvalho AMRS, 2017Novels AntigensLiHypABrazil100%93.7 - 10098.2%90.3 - 10098.3%90.8 - 100100%93.4 - 10055N.C.1N.CCoelho EA, 2016Novels AntigensCcOxBrazil100%85.8 - 100100%85.8 - 100100%N.C100%N.CN.CN.CN.CN.CHRFBrazil100%85.8 - 100100%85.8 - 100100%N.C100%N.CN.CN.CN.CN.CDuarte MC, 2015Novels AntigensTryparedoxin peroxidaseBrazil100%91.8 - 100100%91.2 - 100N.CN.CN.CN.CN.C100%11.0 - 1.0Eukaryotic initiation factor 5aBrazil100%91.8 - 10092.5%79.6 - 98.4N.CN.CN.CN.CN.C96.4%10.9 - 1.0EnolaseBrazil100%91.8 - 10085.0%70.2 - 94.3N.CN.CN.CN.CN.C92.8%0,90.9 - 1.0β-TubulinBrazil100%91.8 - 10082.5%67.2 - 92.7N.CN.CN.CN.CN.C91.6%0,90.9- 1.0Hypothetical protein (LbrM.30.3350)Brazil95.4%91.0 - 10085.0%70.2 - 94.3N.CN.CN.CN.CN.C90.4%10.9 - 1.0Menezes-Souza D, 2014Novels AntigensHSP83.1Brazil93.8%84.9 - 98.395.7%87.9 - 99.195.3%N.C94.3N.CN.C94.8%0,9890.979 - 1.00Dias DS, 2018SLA*L. braziliensis*Brazil1.0%0.4 - 7.9100%93.8 - 100100%2.5 - 10046.6%37.4 - 55.5N.C.N.C.N.C.N.C.*L. infantum*Brazil62.0%46.4 - 75.573.0%60.9 - 82.459.0%44.2 - 73.075.0%62.9 - 84.2N.C.N.C.N.C.N.C.Lima MP, 2017SLA*L. braziliensis*Brazil75.6%60.5 - 87.198.0%89.4 - 99.9N.C.N.C.N.C.N.C.37,5N.C.N.C.N.C.Sato CM, 2017SLA*L. major-* LikeBrazil91.2%81.8 - 96.795.6%87.6 - 99.1N.C.N.C.N.C.N.C.N.C.91.1%N.C.N.C.Coelho EA, 2016SLA*L. braziliensis*Brazil77.4%58.9 -100%83.9 -100N.C.75.0%N.C.N.C.N.C.N.C.N.C.Duarte MC, 2015SLA*L. braziliensis*Brazil65.1%49.1 - 79.057.5%40.9 - 73.0N.C.N.C.N.C.N.C.N.C.61.4%0,60.5 - 0.7Soares KA, 2015SLA*L. mexicana*Brazil90.8%83.5 - 95.180.3%73.9 - 85.471.2%62.7 - 78.494.2%89.4 - 96.9N.C.83.9%N.C.N.C.Cataldo JI, 2010SLA*L. braziliensis*Brazil89.5%80.6 - 95.389.5%80.3 - 95.389.5%81.7 - 94.489.5%81.8 - 94.28,5N.C.0,91880.6 - 95.3Szargiki R, 2009SLA*L. Amazonensis*Brazil71.7%N.C.84.6%N.C.95.5%N.C.39.3%N.C.N.C.N.C.N.C.N.C.*L. braziliensis*Brazil95.0%N.C.92.3%N.C.98.0%N.C.80.0%N.C.N.C.N.C.N.C.N.C.Nascimento LD, 2009SLA*L. braziliensis*Brazil97.4%93.9 - 99.193.7%89.2 - 96.793.9%89.3 - 96.997.3%93.4 - 98.9N.C.N.C.N.C.N.C.Barroso-Freitas APT, 2009SLA*L. braziliensis*Brazil95.7%89.5 - 98.8100%97.7 - 100100%95.9 - 100100%93.8 - 99.3N.C.N.C.N.C.N.C.*L. major-* LikeBrazil78.7%69.1 - 86.582.8%76.0 - 88.373.3%63.5 - 81.686.6%80.2 - 91.7N.C.N.C.N.C.N.C.Vidigal CdeP, 2008SLA*L. braziliensis*Brazil85.4%73.3 - 93.489.6%78.4 - 96.180.4%67.8 - 89.593.7%87.9 - 97.2N.C.N.C.N.C.N.C.Añez N, 2007SLAN.S.Venezuela53.0%43.0 - 61.083.0%73.0 - 89.079.0%68.0 - 86.059.0%50 - 66N.C.N.C.N.C.N.C.Cataldo JI, 2010Enriched membrane fraction*L. braziliensis*Brazil89.5%80.3 - 95.393.4%85.3 - 97.893.2%85.8 - 96.989.9%82.4 - 94.413,6N.C.0,93488.2 - 96.8Barroso-Freitas APT, 2009 *L. braziliensis*Brazil81.5%70.0 - 90.186.2%79.0 - 91.673.4%62.3 - 82.794.7%88.9 - 98.0N.C.N.C.N.C.N.C.IFA*L. major-* LikeBrazil95.4%87.1 - 99.077.7%69.6 - 84.563.5%53.1 - 73.196.9%91.2 - 99.4N.C.N.C.N.C.N.C. Bio-Manguinhos kitBrazil75.4%63.1 - 85.289.2%82.6 - 94.079.6%66.5 - 89.484.8%77.8 - 90.4N.C.N.C.N.C.N.C.Añez N, 2007IFAN.S.Venezuela23.0%16.0 - 31.087.0%78.0 - 92.067.0%51 .0 - 80.059.0%50.0 - 66.0N.C.N.C.N.C.N.C.[^4]

In novel-based ELISAs, only four studies calculated the positive and negative predictive values (PPV and NPV), two calculated the likelihood ratio (LR), three calculated the percentage of accuracy and three the area under the curve (AUC). Regarding SLA-based ELISA tests, in nine studies, the positive and negative predictive values were calculated, the likelihood ratio by two, the percentage of accuracy by three and the AUC by two. Finally, in the two studies that compared IFA methods, the PPV and NPV were calculated ( [Table 3](#t3){ref-type="table"} ).

The novel-based ELISAs showed a sensitivity between 93.8-100% and a specificity between 82.5-100%, with equally high confidence intervals (CI) of 95% ( [Figure 3](#f03){ref-type="fig"} ). The PPV showed values between 98.3-100% and NPV was 100% in the five studies that calculated these data. The accuracy percentage was between 90.4-100%, and the AUC values were between 0.989 -1. The LR values reported in two studies were 50 and 55 ( [Table 3](#t3){ref-type="table"} ).

Figure 3Summary of sensitivity and specificity values of the novel-based ELISAs reported for each antigen.

The SLA-based ELISAs showed an inconsistent and poor performance, with a range of sensitivity between 1-97.4%, and a specificity between 57.5-100%, with equally heterogeneous CI 95% ( [Figure 4](#f04){ref-type="fig"} ). The PPV values ranged from 59- 100%and the NPV values ranged from 39.3-100%. The accuracy percentage ranged from 61.4-91.1% and the two AUC measured were 0.6 and 0.989. The reported LR values were 8.5 and 37.5% ( [Table 3](#t3){ref-type="table"} ).

Figure 4Summary of sensitivity and specificity values of standard ELISA assays based on soluble antigen of specific *Leishmania* species. Observation: the author did not specify the *Leishmania* specie used.

A single study used Enriched Membrane Fraction and reported sensitivity and specificity of 89.5% and 93.4%, respectively. In addition, PPV (93.2%), NPV (89.9%), LR (13.6) and AUC (0.934) were also reported ( [Table 3](#t3){ref-type="table"} ).

Regarding the accuracy of SLA-based ELISAs by leishmania species, *L. (V.) braziliensis* antigens were the most used, showing values from 1- 95.7% of sensitivity and 57.5- 100% of specificity. Two studies used *L. (L.) major* -like and reported values of 85.4- 91.2% of sensitivity and 82.8- 95.6% of specificity. *L. (L.) mexicana* 90.8-80.3%, *L. (L.) amazonensis* 71.7- 84.6% and *L. (L.) infantum* 62-73%, respectively.

The IFA tests were performed using different species of *Leishmania* ( *L. braziliensis, L. major* -Like, Bio-Manguinhos commercial antigen and another that was not specified). Regarding the diagnostic performance of IFAs. These tests showed a sensitivity between 23- 95.4% and a specificity between 77.7- 89.2%. The PPV values ranged from 63.- 79.6% and the NPV values ranged from 69- 96.9% ( [Table 3](#t3){ref-type="table"} ).

Cross-reactivity with Chagas disease
------------------------------------

Ten studies performed comparisons of cross-reactions with serum samples from patients with Chagas disease, and only two reported reactivity (lack of specificity). Among the studies analyzing ELISAs with novel antigens, only one reported 17% (95% CI, 12-27.9) of reactivity in ELISAs based on the recombinant rLb6H antigen^[@B27]^ . As for standard ELISAs based on SLA, several percentages of cross-reactivity were reported according to the species used: *L. major* -Like 69% (95% CI, 66.1 - 83.5)^[@B27]^ , *L. mexicana* 66.7%^[@B35]^ , *L. amazonensis* 10% and *L. braziliensis* 20%^[@B36]^ .

DISCUSSION
==========

Our research shows data that point to a problem regarding the choice of serological methods for the diagnosis of ATL. Several ELISAs using different types of antigens, have been proposed as sensitive tools for the diagnosis of this disease. From the available literature, we analyzed and summarized data on diagnostic accuracy studies of ELISAs based on novel antigens, some of them recombinants. They were compared with standard ELISAs based on soluble *Leishmania* antigens (SLA). Due to the existence of only one study per novel antigen, a meta-analysis was not conducted in this review as at least four studies are necessary to perform a meta-analysis.

Our research question was restricted to the Americas aiming to produce useful evidence for ATL control programs in the region. Since 92.2% of ELISAs included in this systematic review were developed in Brazil and the remaining 7.8% in Venezuela, our results reflect the state of serological diagnostic tests for ATL in Brazil.

Several indicators of diagnostic performance were proposed, such as the percentage of sensitivity and specificity. Novel ELISA antigens showed a high sensitivity and specificity, proving a better diagnostic performance than standard ELISAs (SLA), which showed heterogeneous values. However, the use of paired indicators (sensitivity and specificity) can create a bias when the performance of competing tests is performed, especially if one test does not outperform the other with respect to both indicators. Through a meta-analysis, the diagnostic odds ratio (DOR), which is the only indicator of diagnostic performance, would help to evaluate the diagnostic test performance in the studies objectively^[@B41]^ .

Regarding SLA, the soluble antigens of *L. (V.) braziliensis* showed a better performance than the soluble antigens of the other species used in the serological diagnosis of LTA. In IFA tests, sensitivity and specificity values were similar to those observed in standard ELISAs (SLA). This could be explained by the fact that both, SLA-based ELISAs and IFAs were developed using the same *Leishmania* species.

From the total of 14 studies included in this systematic review, ten made comparisons on cross-reactions with serum samples from patients with Chagas disease, and only two reported the occurrence of cross-reactivity. The only novel-based ELISA that reported cross-reactivity was developed using rLb6H^[@B27]^ . This recombinant antigen had a reactivity of 17%, which is lower when compared to the 69% observed in the SLA-based ELISA of *L. major* -like and 33% with *L. (L.) mexicana* . SLA-based ELISAs of *L. amazonensis* and *L. braziliensis* showed a lower or equal reactivity to rLb6H^[@B20]^ .

The percentage of cross-reactivity to serum samples from patients with Chagas disease, in the serological methods used for the diagnosis of ATL, should be reported to estimate or at least to be aware of the probability of a cross-reactivity. For this reason, when using tests that show a high percentage of cross-reactivity for the diagnosis of ATL, the possibility of a coinfection with *T. cruzi* cannot be ruled out. Any suspicion of coinfection should be investigated using specific Chagas disease tests.

Using the genome sequencing, we can calculate the percentage of similarity of a target protein sequence among species of *Leishmania* and *Trypanosoma cruzi* before they are used as antigen in ELISAs to save time and resources.

There are some limitations in our study. First, the novel antigens as well as soluble antigens of different species of *Leishamnia* are different, resulting in different cut-off values. Second, although the specificity was almost 100%, only a few authors included groups of control patients with diseases other than Chagas, such as tuberculosis, histoplasmosis, malaria and paracoccidioidomycosis. Finally, some studies included in this systematic review did not analyze positive and negative predictive values, and only a few showed values of likelihood ratio, area under the curve and accuracy. The lack of these data limited the comparison between the methods analyzed with regard to indicators such as sensitivity and specificity. Using paired indicators can be a disadvantage to compare the performance of competing tests, especially if one test does not outperform the other with respect to both indicators^[@B41]^ . Both, sensitivity and specificity provide information about the probability of obtaining an accurate result (positive or negative) depending on the true condition of the patient with respect to the disease. However, PPV and NPV are useful in clinical practice informing the probability of the patient to be really sick or healthy according to a positive or negative result.

In this systematic review, the novel ELISAs antigens showed an advantage in sensitivity (95.4-100%) and specificity (82.5-100%) compared to standard ELISAs based on SLA (1%-97.4% and 57.5%-100%, respectively). These ELISAs based on SLA, together with IFAs showed heterogeneous accuracy values.

The development of new serological diagnostic tools, with higher accuracy and reliability in the diagnosis of ATL and capable of reducing the risk of cross-reactivity with Chagas disease or other infectious diseases is of great importance for laboratory diagnosis, analysis of treatment efficacy, epidemiology and disease control.
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